UNSPSC 51172819: Carbamide peroxide/glycerol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.

UNSPSC 51172819 Carbamide peroxide/glycerol is a Commodity code covering pharmaceutical and over-the-counter products that state and local governments procure through cooperative purchasing arrangements and direct supply agreements. State and local buyers use this code to source generic multi-source pharmaceuticals and OTC products for distribution across government health facilities, correctional institutions, and other public health settings. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent issuing body, establishing coordinated procurement vehicles that span multiple states. Vendors competing for this work must comply with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and FDA requirements, maintain relationships with authorized pharmaceutical wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), and accept performance penalties ranging from $200 to $1,500 per violation for late reporting or onboarding failures. Pricing is weighted at 75 percent of evaluation, with administrative and technical compliance factors accounting for the remainder, and awarded vendors agree to a 3 percent administrative fee on all contract purchases.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802), due March 26, 2026, represents the most recent solicitation under this code. The procurement spans participating state and local government facilities across Minnesota and Oregon, with contract terms of two years for new vendors and optional extensions at MMCAP's discretion. Products must be available in the marketplace by May 15, 2026, and resulting agreements become effective July 1, 2026. Vendors must submit detailed product information including NDC codes, SKUs, UPCs, generic descriptions, strength, dosage form, and packaging configurations, and maintain comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs, with award values and budget ranges not disclosed in the RFP.